Elsevier, a world-leading provider of scientific, technical and medical information products and services, has announced the launch of a web-based version of Pathway Studio, a research solution for biologists. Additionally, Pathway Studio now incorporates biological data from Elsevier’s biology journals in addition to journals obtained through collaboration with third-party publishers. The addition of this data to Pathway Studio results in a resource that is unparalleled in depth and coverage of molecular interactions with supporting evidence. The new web-based version broadly extends access to researchers to reveal new insights and to assist with critical decision making.
“Currently, molecular facts are scattered in individual articles and researchers must gather and integrate these to advance new discovery,” said Jaqui Mason, Product Development Director for Biology Products at Elsevier. “Pathway Studio presents these facts in a graphical context to help researchers assemble biological models that can be applied to target discovery programs, identify potential diagnostics, and reposition drugs. The new content included in Pathway Studio can expose a more complete picture in biology, which reduces risk, increases efficiency, and ultimately improves success rate whether it’s bringing a new drug to market or exploring a theory.”
“Incorporation of facts from Elsevier’s biology journals into Pathway Studio, as well as building a pipeline of fresh data through our collaboration with third-party publishers, enables us to deliver additional value to our portfolio of solutions across biology, chemistry, and medicine in order to better serve the needs of customers in early discovery and biology researchers,” said Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group. “Offering a web-based version of Pathway Studio has allowed us to streamline common tasks and make the benefit of this content accessible to a broader and more general user-base.”
The new web-based Pathway Studio adds additional early discovery capability to Elsevier’s suite of life science information solutions which include Reaxys, the leading chemistry discovery engine, PharmaPendium which supports regulatory and safety activities, TargetInsights, a biological literature search system for early discovery and Quosa, which automates literature management workflows with applications in pharmacovigilance and medical affairs. This suite effectively delivers complementary solutions spanning early discovery, pre-clinical, clinical and post-launch workflows.